nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclosporine—systemic lupus erythematosus—ankylosing spondylitis	0.225	0.366	CtDrD
Cyclosporine—rheumatoid arthritis—ankylosing spondylitis	0.213	0.345	CtDrD
Cyclosporine—psoriasis—ankylosing spondylitis	0.178	0.289	CtDrD
Cyclosporine—ABCC10—Methotrexate—ankylosing spondylitis	0.0241	0.0805	CbGbCtD
Cyclosporine—SLCO1B1—Sulfasalazine—ankylosing spondylitis	0.0196	0.0653	CbGbCtD
Cyclosporine—SLCO1A2—Prednisolone—ankylosing spondylitis	0.0176	0.0586	CbGbCtD
Cyclosporine—ABCC2—Sulfasalazine—ankylosing spondylitis	0.0172	0.0573	CbGbCtD
Cyclosporine—SLCO1A2—Prednisone—ankylosing spondylitis	0.0166	0.0553	CbGbCtD
Cyclosporine—ABCB11—Dexamethasone—ankylosing spondylitis	0.0163	0.0544	CbGbCtD
Cyclosporine—ABCG2—Sulfasalazine—ankylosing spondylitis	0.0156	0.0518	CbGbCtD
Cyclosporine—ABCC3—Methotrexate—ankylosing spondylitis	0.0152	0.0506	CbGbCtD
Cyclosporine—SLCO1A2—Dexamethasone—ankylosing spondylitis	0.0104	0.0345	CbGbCtD
Cyclosporine—ABCC1—Methotrexate—ankylosing spondylitis	0.00932	0.0311	CbGbCtD
Cyclosporine—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.00862	0.0287	CbGbCtD
Cyclosporine—ABCC2—Dexamethasone—ankylosing spondylitis	0.00858	0.0286	CbGbCtD
Cyclosporine—SLCO1A2—Methotrexate—ankylosing spondylitis	0.00832	0.0277	CbGbCtD
Cyclosporine—SLCO1B1—Methotrexate—ankylosing spondylitis	0.00785	0.0262	CbGbCtD
Cyclosporine—ABCG2—Dexamethasone—ankylosing spondylitis	0.00776	0.0259	CbGbCtD
Cyclosporine—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0074	0.0247	CbGbCtD
Cyclosporine—ABCC2—Methotrexate—ankylosing spondylitis	0.0069	0.023	CbGbCtD
Cyclosporine—ABCG2—Methotrexate—ankylosing spondylitis	0.00624	0.0208	CbGbCtD
Cyclosporine—CYP3A7—Dexamethasone—ankylosing spondylitis	0.00573	0.0191	CbGbCtD
Cyclosporine—CYP3A7-CYP3A51P—Dexamethasone—ankylosing spondylitis	0.00573	0.0191	CbGbCtD
Cyclosporine—CYP2C19—Prednisone—ankylosing spondylitis	0.00556	0.0185	CbGbCtD
Cyclosporine—SLC22A6—Methotrexate—ankylosing spondylitis	0.00505	0.0168	CbGbCtD
Cyclosporine—ABCB1—Betamethasone—ankylosing spondylitis	0.00481	0.016	CbGbCtD
Cyclosporine—ABCB1—Prednisolone—ankylosing spondylitis	0.00475	0.0158	CbGbCtD
Cyclosporine—ABCB1—Prednisone—ankylosing spondylitis	0.00448	0.0149	CbGbCtD
Cyclosporine—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.00443	0.0148	CbGbCtD
Cyclosporine—CYP3A5—Dexamethasone—ankylosing spondylitis	0.0043	0.0143	CbGbCtD
Cyclosporine—CYP2C8—Dexamethasone—ankylosing spondylitis	0.00413	0.0138	CbGbCtD
Cyclosporine—CYP2C19—Dexamethasone—ankylosing spondylitis	0.00347	0.0116	CbGbCtD
Cyclosporine—CYP3A4—Triamcinolone—ankylosing spondylitis	0.00336	0.0112	CbGbCtD
Cyclosporine—CYP2C9—Dexamethasone—ankylosing spondylitis	0.00288	0.00961	CbGbCtD
Cyclosporine—CYP3A4—Betamethasone—ankylosing spondylitis	0.00288	0.00961	CbGbCtD
Cyclosporine—CYP3A4—Prednisolone—ankylosing spondylitis	0.00284	0.00948	CbGbCtD
Cyclosporine—ABCB1—Dexamethasone—ankylosing spondylitis	0.0028	0.00933	CbGbCtD
Cyclosporine—CYP3A4—Prednisone—ankylosing spondylitis	0.00269	0.00895	CbGbCtD
Cyclosporine—CYP2D6—Dexamethasone—ankylosing spondylitis	0.00264	0.00879	CbGbCtD
Cyclosporine—ABCB1—Methotrexate—ankylosing spondylitis	0.00225	0.0075	CbGbCtD
Cyclosporine—CYP3A4—Dexamethasone—ankylosing spondylitis	0.00168	0.00559	CbGbCtD
Cyclosporine—FKBP1B—Stimuli-sensing channels—ANO6—ankylosing spondylitis	0.00162	0.168	CbGpPWpGaD
Cyclosporine—FKBP1B—Ion channel transport—ANO6—ankylosing spondylitis	0.00105	0.109	CbGpPWpGaD
Cyclosporine—SLC10A2—Orphan transporters—ANO6—ankylosing spondylitis	0.000734	0.0762	CbGpPWpGaD
Cyclosporine—PPP3R2—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000697	0.0723	CbGpPWpGaD
Cyclosporine—FKBP1B—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000367	0.0381	CbGpPWpGaD
Cyclosporine—PPIB—Collagen formation—MMP3—ankylosing spondylitis	0.000295	0.0306	CbGpPWpGaD
Cyclosporine—FKBP1A—TGF-beta Receptor Signaling—RUNX3—ankylosing spondylitis	0.000289	0.03	CbGpPWpGaD
Cyclosporine—PPP3R2—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000237	0.0246	CbGpPWpGaD
Cyclosporine—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.000235	0.0243	CbGpPWpGaD
Cyclosporine—PPP3CA—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000219	0.0227	CbGpPWpGaD
Cyclosporine—PPP3CA—BCR signaling pathway—CD79A—ankylosing spondylitis	0.00019	0.0197	CbGpPWpGaD
Cyclosporine—SLC10A2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000179	0.0186	CbGpPWpGaD
Cyclosporine—ABCC10—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000169	0.0175	CbGpPWpGaD
Cyclosporine—PPP3R2—Alzheimers Disease—TNF—ankylosing spondylitis	0.000164	0.017	CbGpPWpGaD
Cyclosporine—PPIB—Extracellular matrix organization—MMP3—ankylosing spondylitis	0.000118	0.0122	CbGpPWpGaD
Cyclosporine—FKBP4—Cellular responses to stress—IL1A—ankylosing spondylitis	0.000118	0.0122	CbGpPWpGaD
Cyclosporine—PPIA—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	9.9e-05	0.0103	CbGpPWpGaD
Cyclosporine—PPP3CA—Spinal Cord Injury—IL1A—ankylosing spondylitis	9.9e-05	0.0103	CbGpPWpGaD
Cyclosporine—PPP3CA—Amyotrophic lateral sclerosis (ALS)—TNF—ankylosing spondylitis	9.27e-05	0.00962	CbGpPWpGaD
Cyclosporine—PPP3R2—MAPK Signaling Pathway—TNF—ankylosing spondylitis	8.97e-05	0.00931	CbGpPWpGaD
Cyclosporine—PPP3CA—Spinal Cord Injury—TLR4—ankylosing spondylitis	7.93e-05	0.00823	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—KIR3DL1—ankylosing spondylitis	7.85e-05	0.00815	CbGpPWpGaD
Cyclosporine—FKBP1A—Spinal Cord Injury—IL1A—ankylosing spondylitis	7.68e-05	0.00796	CbGpPWpGaD
Cyclosporine—PPP3CA—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	7.46e-05	0.00774	CbGpPWpGaD
Cyclosporine—FKBP1B—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	7.22e-05	0.00749	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—CARD9—ankylosing spondylitis	7.08e-05	0.00735	CbGpPWpGaD
Cyclosporine—PPP3CA—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	6.9e-05	0.00716	CbGpPWpGaD
Cyclosporine—PPIA—Disease—ANTXR2—ankylosing spondylitis	6.61e-05	0.00686	CbGpPWpGaD
Cyclosporine—ABCC3—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	6.53e-05	0.00677	CbGpPWpGaD
Cyclosporine—PPIA—HIV Infection—HLA-A—ankylosing spondylitis	6.44e-05	0.00668	CbGpPWpGaD
Cyclosporine—FKBP1A—Spinal Cord Injury—TLR4—ankylosing spondylitis	6.15e-05	0.00638	CbGpPWpGaD
Cyclosporine—Discomfort—Methylprednisolone—ankylosing spondylitis	5.74e-05	0.000779	CcSEcCtD
Cyclosporine—Dry mouth—Triamcinolone—ankylosing spondylitis	5.7e-05	0.000773	CcSEcCtD
Cyclosporine—SLCO1A2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	5.69e-05	0.0059	CbGpPWpGaD
Cyclosporine—Renal failure—Methotrexate—ankylosing spondylitis	5.68e-05	0.000771	CcSEcCtD
Cyclosporine—Angioedema—Betamethasone—ankylosing spondylitis	5.67e-05	0.000769	CcSEcCtD
Cyclosporine—Angioedema—Dexamethasone—ankylosing spondylitis	5.67e-05	0.000769	CcSEcCtD
Cyclosporine—Stomatitis—Methotrexate—ankylosing spondylitis	5.64e-05	0.000764	CcSEcCtD
Cyclosporine—Angiopathy—Prednisone—ankylosing spondylitis	5.64e-05	0.000764	CcSEcCtD
Cyclosporine—Conjunctivitis—Methotrexate—ankylosing spondylitis	5.62e-05	0.000762	CcSEcCtD
Cyclosporine—Confusional state—Methylprednisolone—ankylosing spondylitis	5.62e-05	0.000762	CcSEcCtD
Cyclosporine—Malaise—Betamethasone—ankylosing spondylitis	5.6e-05	0.000759	CcSEcCtD
Cyclosporine—Malaise—Dexamethasone—ankylosing spondylitis	5.6e-05	0.000759	CcSEcCtD
Cyclosporine—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	5.59e-05	0.000757	CcSEcCtD
Cyclosporine—Oedema—Triamcinolone—ankylosing spondylitis	5.59e-05	0.000757	CcSEcCtD
Cyclosporine—Vertigo—Dexamethasone—ankylosing spondylitis	5.58e-05	0.000757	CcSEcCtD
Cyclosporine—Vertigo—Betamethasone—ankylosing spondylitis	5.58e-05	0.000757	CcSEcCtD
Cyclosporine—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	5.57e-05	0.000756	CcSEcCtD
Cyclosporine—Arrhythmia—Prednisone—ankylosing spondylitis	5.55e-05	0.000753	CcSEcCtD
Cyclosporine—Infection—Triamcinolone—ankylosing spondylitis	5.55e-05	0.000752	CcSEcCtD
Cyclosporine—Infection—Methylprednisolone—ankylosing spondylitis	5.54e-05	0.000751	CcSEcCtD
Cyclosporine—Haematuria—Methotrexate—ankylosing spondylitis	5.51e-05	0.000748	CcSEcCtD
Cyclosporine—PPP3CA—Disease—ANTXR2—ankylosing spondylitis	5.49e-05	0.0057	CbGpPWpGaD
Cyclosporine—Insomnia—Prednisolone—ankylosing spondylitis	5.49e-05	0.000745	CcSEcCtD
Cyclosporine—Alopecia—Prednisone—ankylosing spondylitis	5.49e-05	0.000744	CcSEcCtD
Cyclosporine—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	5.47e-05	0.000742	CcSEcCtD
Cyclosporine—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	5.47e-05	0.000741	CcSEcCtD
Cyclosporine—Epistaxis—Methotrexate—ankylosing spondylitis	5.45e-05	0.00074	CcSEcCtD
Cyclosporine—Paraesthesia—Prednisolone—ankylosing spondylitis	5.45e-05	0.00074	CcSEcCtD
Cyclosporine—Mental disorder—Prednisone—ankylosing spondylitis	5.44e-05	0.000738	CcSEcCtD
Cyclosporine—FKBP1A—TGF-beta Receptor Signaling—TNF—ankylosing spondylitis	5.43e-05	0.00563	CbGpPWpGaD
Cyclosporine—Skin disorder—Methylprednisolone—ankylosing spondylitis	5.41e-05	0.000734	CcSEcCtD
Cyclosporine—Malnutrition—Prednisone—ankylosing spondylitis	5.41e-05	0.000733	CcSEcCtD
Cyclosporine—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	5.4e-05	0.000732	CcSEcCtD
Cyclosporine—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	5.39e-05	0.000731	CcSEcCtD
Cyclosporine—Convulsion—Betamethasone—ankylosing spondylitis	5.38e-05	0.00073	CcSEcCtD
Cyclosporine—Convulsion—Dexamethasone—ankylosing spondylitis	5.38e-05	0.00073	CcSEcCtD
Cyclosporine—Hypertension—Betamethasone—ankylosing spondylitis	5.36e-05	0.000727	CcSEcCtD
Cyclosporine—Hypertension—Dexamethasone—ankylosing spondylitis	5.36e-05	0.000727	CcSEcCtD
Cyclosporine—SLC22A6—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	5.34e-05	0.00554	CbGpPWpGaD
Cyclosporine—Myalgia—Dexamethasone—ankylosing spondylitis	5.29e-05	0.000717	CcSEcCtD
Cyclosporine—Myalgia—Betamethasone—ankylosing spondylitis	5.29e-05	0.000717	CcSEcCtD
Cyclosporine—Anxiety—Dexamethasone—ankylosing spondylitis	5.27e-05	0.000714	CcSEcCtD
Cyclosporine—Anxiety—Betamethasone—ankylosing spondylitis	5.27e-05	0.000714	CcSEcCtD
Cyclosporine—Discomfort—Dexamethasone—ankylosing spondylitis	5.22e-05	0.000708	CcSEcCtD
Cyclosporine—Discomfort—Betamethasone—ankylosing spondylitis	5.22e-05	0.000708	CcSEcCtD
Cyclosporine—Haemoglobin—Methotrexate—ankylosing spondylitis	5.22e-05	0.000708	CcSEcCtD
Cyclosporine—Pain—Prednisolone—ankylosing spondylitis	5.19e-05	0.000704	CcSEcCtD
Cyclosporine—Hepatitis—Methotrexate—ankylosing spondylitis	5.19e-05	0.000704	CcSEcCtD
Cyclosporine—Haemorrhage—Methotrexate—ankylosing spondylitis	5.19e-05	0.000704	CcSEcCtD
Cyclosporine—ABCC2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	5.18e-05	0.00537	CbGpPWpGaD
Cyclosporine—PPP3CA—Alzheimers Disease—TNF—ankylosing spondylitis	5.16e-05	0.00536	CbGpPWpGaD
Cyclosporine—Pharyngitis—Methotrexate—ankylosing spondylitis	5.15e-05	0.000699	CcSEcCtD
Cyclosporine—Urinary tract disorder—Methotrexate—ankylosing spondylitis	5.13e-05	0.000695	CcSEcCtD
Cyclosporine—ABCC1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	5.12e-05	0.00531	CbGpPWpGaD
Cyclosporine—Vision blurred—Prednisone—ankylosing spondylitis	5.1e-05	0.000691	CcSEcCtD
Cyclosporine—Urethral disorder—Methotrexate—ankylosing spondylitis	5.09e-05	0.00069	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	5.09e-05	0.00069	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	5.08e-05	0.000689	CcSEcCtD
Cyclosporine—Oedema—Dexamethasone—ankylosing spondylitis	5.07e-05	0.000687	CcSEcCtD
Cyclosporine—Oedema—Betamethasone—ankylosing spondylitis	5.07e-05	0.000687	CcSEcCtD
Cyclosporine—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	5.07e-05	0.000687	CcSEcCtD
Cyclosporine—Anaphylactic shock—Betamethasone—ankylosing spondylitis	5.07e-05	0.000687	CcSEcCtD
Cyclosporine—Insomnia—Triamcinolone—ankylosing spondylitis	5.05e-05	0.000685	CcSEcCtD
Cyclosporine—Insomnia—Methylprednisolone—ankylosing spondylitis	5.04e-05	0.000684	CcSEcCtD
Cyclosporine—Infection—Betamethasone—ankylosing spondylitis	5.03e-05	0.000683	CcSEcCtD
Cyclosporine—Infection—Dexamethasone—ankylosing spondylitis	5.03e-05	0.000683	CcSEcCtD
Cyclosporine—Ill-defined disorder—Prednisone—ankylosing spondylitis	5.02e-05	0.00068	CcSEcCtD
Cyclosporine—Paraesthesia—Triamcinolone—ankylosing spondylitis	5.02e-05	0.00068	CcSEcCtD
Cyclosporine—Feeling abnormal—Prednisolone—ankylosing spondylitis	5e-05	0.000679	CcSEcCtD
Cyclosporine—Paraesthesia—Methylprednisolone—ankylosing spondylitis	5e-05	0.000679	CcSEcCtD
Cyclosporine—Visual impairment—Methotrexate—ankylosing spondylitis	5e-05	0.000678	CcSEcCtD
Cyclosporine—Anaemia—Prednisone—ankylosing spondylitis	5e-05	0.000678	CcSEcCtD
Cyclosporine—Dyspnoea—Triamcinolone—ankylosing spondylitis	4.98e-05	0.000675	CcSEcCtD
Cyclosporine—Nervous system disorder—Betamethasone—ankylosing spondylitis	4.97e-05	0.000674	CcSEcCtD
Cyclosporine—Nervous system disorder—Dexamethasone—ankylosing spondylitis	4.97e-05	0.000674	CcSEcCtD
Cyclosporine—Agitation—Prednisone—ankylosing spondylitis	4.97e-05	0.000674	CcSEcCtD
Cyclosporine—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	4.96e-05	0.000673	CcSEcCtD
Cyclosporine—Thrombocytopenia—Betamethasone—ankylosing spondylitis	4.96e-05	0.000673	CcSEcCtD
Cyclosporine—Angioedema—Prednisone—ankylosing spondylitis	4.94e-05	0.00067	CcSEcCtD
Cyclosporine—PPP3CA—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	4.92e-05	0.0051	CbGpPWpGaD
Cyclosporine—Dyspepsia—Triamcinolone—ankylosing spondylitis	4.92e-05	0.000667	CcSEcCtD
Cyclosporine—Dyspepsia—Methylprednisolone—ankylosing spondylitis	4.91e-05	0.000665	CcSEcCtD
Cyclosporine—Hyperhidrosis—Betamethasone—ankylosing spondylitis	4.9e-05	0.000664	CcSEcCtD
Cyclosporine—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	4.9e-05	0.000664	CcSEcCtD
Cyclosporine—Malaise—Prednisone—ankylosing spondylitis	4.88e-05	0.000661	CcSEcCtD
Cyclosporine—SLCO1B1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	4.86e-05	0.00504	CbGpPWpGaD
Cyclosporine—Vertigo—Prednisone—ankylosing spondylitis	4.86e-05	0.000659	CcSEcCtD
Cyclosporine—Tinnitus—Methotrexate—ankylosing spondylitis	4.84e-05	0.000656	CcSEcCtD
Cyclosporine—Anorexia—Betamethasone—ankylosing spondylitis	4.83e-05	0.000655	CcSEcCtD
Cyclosporine—Anorexia—Dexamethasone—ankylosing spondylitis	4.83e-05	0.000655	CcSEcCtD
Cyclosporine—Urticaria—Prednisolone—ankylosing spondylitis	4.82e-05	0.000654	CcSEcCtD
Cyclosporine—Fatigue—Triamcinolone—ankylosing spondylitis	4.82e-05	0.000653	CcSEcCtD
Cyclosporine—Fatigue—Methylprednisolone—ankylosing spondylitis	4.8e-05	0.000652	CcSEcCtD
Cyclosporine—Pain—Triamcinolone—ankylosing spondylitis	4.78e-05	0.000648	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—IL1R2—ankylosing spondylitis	4.76e-05	0.00494	CbGpPWpGaD
Cyclosporine—Angiopathy—Methotrexate—ankylosing spondylitis	4.71e-05	0.000639	CcSEcCtD
Cyclosporine—Convulsion—Prednisone—ankylosing spondylitis	4.69e-05	0.000635	CcSEcCtD
Cyclosporine—Mediastinal disorder—Methotrexate—ankylosing spondylitis	4.68e-05	0.000634	CcSEcCtD
Cyclosporine—Hypertension—Prednisone—ankylosing spondylitis	4.67e-05	0.000633	CcSEcCtD
Cyclosporine—Chills—Methotrexate—ankylosing spondylitis	4.66e-05	0.000632	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	4.62e-05	0.000626	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	4.62e-05	0.000626	CcSEcCtD
Cyclosporine—Arthralgia—Prednisone—ankylosing spondylitis	4.6e-05	0.000624	CcSEcCtD
Cyclosporine—Myalgia—Prednisone—ankylosing spondylitis	4.6e-05	0.000624	CcSEcCtD
Cyclosporine—Feeling abnormal—Triamcinolone—ankylosing spondylitis	4.6e-05	0.000624	CcSEcCtD
Cyclosporine—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	4.59e-05	0.000623	CcSEcCtD
Cyclosporine—Anxiety—Prednisone—ankylosing spondylitis	4.59e-05	0.000622	CcSEcCtD
Cyclosporine—Alopecia—Methotrexate—ankylosing spondylitis	4.59e-05	0.000622	CcSEcCtD
Cyclosporine—Insomnia—Dexamethasone—ankylosing spondylitis	4.58e-05	0.000622	CcSEcCtD
Cyclosporine—Insomnia—Betamethasone—ankylosing spondylitis	4.58e-05	0.000622	CcSEcCtD
Cyclosporine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	4.57e-05	0.00062	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	4.56e-05	0.000618	CcSEcCtD
Cyclosporine—Paraesthesia—Betamethasone—ankylosing spondylitis	4.55e-05	0.000617	CcSEcCtD
Cyclosporine—Paraesthesia—Dexamethasone—ankylosing spondylitis	4.55e-05	0.000617	CcSEcCtD
Cyclosporine—Discomfort—Prednisone—ankylosing spondylitis	4.55e-05	0.000617	CcSEcCtD
Cyclosporine—Mental disorder—Methotrexate—ankylosing spondylitis	4.55e-05	0.000617	CcSEcCtD
Cyclosporine—Malnutrition—Methotrexate—ankylosing spondylitis	4.52e-05	0.000613	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—ERAP1—ankylosing spondylitis	4.51e-05	0.00468	CbGpPWpGaD
Cyclosporine—ABCG2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	4.5e-05	0.00467	CbGpPWpGaD
Cyclosporine—Hypersensitivity—Prednisolone—ankylosing spondylitis	4.47e-05	0.000607	CcSEcCtD
Cyclosporine—Dyspepsia—Betamethasone—ankylosing spondylitis	4.46e-05	0.000605	CcSEcCtD
Cyclosporine—Dyspepsia—Dexamethasone—ankylosing spondylitis	4.46e-05	0.000605	CcSEcCtD
Cyclosporine—PPP3CA—Innate Immune System—HLA-C—ankylosing spondylitis	4.45e-05	0.00461	CbGpPWpGaD
Cyclosporine—Urticaria—Triamcinolone—ankylosing spondylitis	4.44e-05	0.000602	CcSEcCtD
Cyclosporine—Urticaria—Methylprednisolone—ankylosing spondylitis	4.43e-05	0.0006	CcSEcCtD
Cyclosporine—Dysgeusia—Methotrexate—ankylosing spondylitis	4.43e-05	0.0006	CcSEcCtD
Cyclosporine—Body temperature increased—Triamcinolone—ankylosing spondylitis	4.42e-05	0.000599	CcSEcCtD
Cyclosporine—Anaphylactic shock—Prednisone—ankylosing spondylitis	4.41e-05	0.000598	CcSEcCtD
Cyclosporine—Oedema—Prednisone—ankylosing spondylitis	4.41e-05	0.000598	CcSEcCtD
Cyclosporine—Abdominal pain—Methylprednisolone—ankylosing spondylitis	4.41e-05	0.000597	CcSEcCtD
Cyclosporine—Decreased appetite—Dexamethasone—ankylosing spondylitis	4.41e-05	0.000597	CcSEcCtD
Cyclosporine—Decreased appetite—Betamethasone—ankylosing spondylitis	4.41e-05	0.000597	CcSEcCtD
Cyclosporine—Infection—Prednisone—ankylosing spondylitis	4.38e-05	0.000595	CcSEcCtD
Cyclosporine—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	4.38e-05	0.000593	CcSEcCtD
Cyclosporine—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	4.38e-05	0.000593	CcSEcCtD
Cyclosporine—Fatigue—Betamethasone—ankylosing spondylitis	4.37e-05	0.000593	CcSEcCtD
Cyclosporine—Fatigue—Dexamethasone—ankylosing spondylitis	4.37e-05	0.000593	CcSEcCtD
Cyclosporine—Pain—Dexamethasone—ankylosing spondylitis	4.33e-05	0.000588	CcSEcCtD
Cyclosporine—Pain—Betamethasone—ankylosing spondylitis	4.33e-05	0.000588	CcSEcCtD
Cyclosporine—Nervous system disorder—Prednisone—ankylosing spondylitis	4.33e-05	0.000587	CcSEcCtD
Cyclosporine—Skin disorder—Prednisone—ankylosing spondylitis	4.29e-05	0.000581	CcSEcCtD
Cyclosporine—Hyperhidrosis—Prednisone—ankylosing spondylitis	4.27e-05	0.000579	CcSEcCtD
Cyclosporine—FKBP1A—Disease—ANTXR2—ankylosing spondylitis	4.26e-05	0.00442	CbGpPWpGaD
Cyclosporine—Vision blurred—Methotrexate—ankylosing spondylitis	4.26e-05	0.000578	CcSEcCtD
Cyclosporine—Anorexia—Prednisone—ankylosing spondylitis	4.21e-05	0.00057	CcSEcCtD
Cyclosporine—Ill-defined disorder—Methotrexate—ankylosing spondylitis	4.19e-05	0.000569	CcSEcCtD
Cyclosporine—Anaemia—Methotrexate—ankylosing spondylitis	4.18e-05	0.000566	CcSEcCtD
Cyclosporine—Feeling abnormal—Betamethasone—ankylosing spondylitis	4.18e-05	0.000566	CcSEcCtD
Cyclosporine—Feeling abnormal—Dexamethasone—ankylosing spondylitis	4.18e-05	0.000566	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	4.14e-05	0.000562	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	4.14e-05	0.000562	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—CARD9—ankylosing spondylitis	4.13e-05	0.00428	CbGpPWpGaD
Cyclosporine—Hypersensitivity—Triamcinolone—ankylosing spondylitis	4.11e-05	0.000558	CcSEcCtD
Cyclosporine—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	4.11e-05	0.000557	CcSEcCtD
Cyclosporine—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	4.1e-05	0.00425	CbGpPWpGaD
Cyclosporine—Malaise—Methotrexate—ankylosing spondylitis	4.08e-05	0.000553	CcSEcCtD
Cyclosporine—Vertigo—Methotrexate—ankylosing spondylitis	4.06e-05	0.000551	CcSEcCtD
Cyclosporine—Leukopenia—Methotrexate—ankylosing spondylitis	4.05e-05	0.000549	CcSEcCtD
Cyclosporine—Urticaria—Betamethasone—ankylosing spondylitis	4.03e-05	0.000546	CcSEcCtD
Cyclosporine—Urticaria—Dexamethasone—ankylosing spondylitis	4.03e-05	0.000546	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	4.02e-05	0.000545	CcSEcCtD
Cyclosporine—Dizziness—Prednisolone—ankylosing spondylitis	4.02e-05	0.000545	CcSEcCtD
Cyclosporine—Asthenia—Triamcinolone—ankylosing spondylitis	4.01e-05	0.000543	CcSEcCtD
Cyclosporine—Abdominal pain—Dexamethasone—ankylosing spondylitis	4.01e-05	0.000543	CcSEcCtD
Cyclosporine—Body temperature increased—Betamethasone—ankylosing spondylitis	4.01e-05	0.000543	CcSEcCtD
Cyclosporine—Body temperature increased—Dexamethasone—ankylosing spondylitis	4.01e-05	0.000543	CcSEcCtD
Cyclosporine—Abdominal pain—Betamethasone—ankylosing spondylitis	4.01e-05	0.000543	CcSEcCtD
Cyclosporine—Asthenia—Methylprednisolone—ankylosing spondylitis	4e-05	0.000542	CcSEcCtD
Cyclosporine—Insomnia—Prednisone—ankylosing spondylitis	3.99e-05	0.000541	CcSEcCtD
Cyclosporine—Paraesthesia—Prednisone—ankylosing spondylitis	3.96e-05	0.000537	CcSEcCtD
Cyclosporine—Pruritus—Triamcinolone—ankylosing spondylitis	3.95e-05	0.000536	CcSEcCtD
Cyclosporine—Cough—Methotrexate—ankylosing spondylitis	3.94e-05	0.000535	CcSEcCtD
Cyclosporine—Pruritus—Methylprednisolone—ankylosing spondylitis	3.94e-05	0.000535	CcSEcCtD
Cyclosporine—Convulsion—Methotrexate—ankylosing spondylitis	3.92e-05	0.000531	CcSEcCtD
Cyclosporine—PPIA—Disease—B3GNT2—ankylosing spondylitis	3.9e-05	0.00404	CbGpPWpGaD
Cyclosporine—Dyspepsia—Prednisone—ankylosing spondylitis	3.88e-05	0.000527	CcSEcCtD
Cyclosporine—Arthralgia—Methotrexate—ankylosing spondylitis	3.85e-05	0.000522	CcSEcCtD
Cyclosporine—Myalgia—Methotrexate—ankylosing spondylitis	3.85e-05	0.000522	CcSEcCtD
Cyclosporine—Chest pain—Methotrexate—ankylosing spondylitis	3.85e-05	0.000522	CcSEcCtD
Cyclosporine—Decreased appetite—Prednisone—ankylosing spondylitis	3.84e-05	0.00052	CcSEcCtD
Cyclosporine—Rash—Prednisolone—ankylosing spondylitis	3.83e-05	0.000519	CcSEcCtD
Cyclosporine—Dermatitis—Prednisolone—ankylosing spondylitis	3.83e-05	0.000519	CcSEcCtD
Cyclosporine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	3.82e-05	0.000518	CcSEcCtD
Cyclosporine—Diarrhoea—Methylprednisolone—ankylosing spondylitis	3.81e-05	0.000517	CcSEcCtD
Cyclosporine—Fatigue—Prednisone—ankylosing spondylitis	3.8e-05	0.000516	CcSEcCtD
Cyclosporine—Headache—Prednisolone—ankylosing spondylitis	3.8e-05	0.000516	CcSEcCtD
Cyclosporine—Discomfort—Methotrexate—ankylosing spondylitis	3.8e-05	0.000516	CcSEcCtD
Cyclosporine—Constipation—Prednisone—ankylosing spondylitis	3.77e-05	0.000512	CcSEcCtD
Cyclosporine—SLC10A2—Metabolism—B3GNT2—ankylosing spondylitis	3.75e-05	0.00389	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	3.75e-05	0.00389	CbGpPWpGaD
Cyclosporine—PPP3CA—Spinal Cord Injury—TNF—ankylosing spondylitis	3.75e-05	0.00389	CbGpPWpGaD
Cyclosporine—Confusional state—Methotrexate—ankylosing spondylitis	3.72e-05	0.000504	CcSEcCtD
Cyclosporine—Dizziness—Triamcinolone—ankylosing spondylitis	3.69e-05	0.000501	CcSEcCtD
Cyclosporine—Anaphylactic shock—Methotrexate—ankylosing spondylitis	3.69e-05	0.0005	CcSEcCtD
Cyclosporine—Dizziness—Methylprednisolone—ankylosing spondylitis	3.69e-05	0.0005	CcSEcCtD
Cyclosporine—Infection—Methotrexate—ankylosing spondylitis	3.66e-05	0.000497	CcSEcCtD
Cyclosporine—Feeling abnormal—Prednisone—ankylosing spondylitis	3.64e-05	0.000493	CcSEcCtD
Cyclosporine—Asthenia—Betamethasone—ankylosing spondylitis	3.64e-05	0.000493	CcSEcCtD
Cyclosporine—Asthenia—Dexamethasone—ankylosing spondylitis	3.64e-05	0.000493	CcSEcCtD
Cyclosporine—Nervous system disorder—Methotrexate—ankylosing spondylitis	3.62e-05	0.000491	CcSEcCtD
Cyclosporine—Thrombocytopenia—Methotrexate—ankylosing spondylitis	3.61e-05	0.00049	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Prednisone—ankylosing spondylitis	3.61e-05	0.000489	CcSEcCtD
Cyclosporine—Nausea—Prednisolone—ankylosing spondylitis	3.61e-05	0.000489	CcSEcCtD
Cyclosporine—Pruritus—Betamethasone—ankylosing spondylitis	3.59e-05	0.000486	CcSEcCtD
Cyclosporine—Pruritus—Dexamethasone—ankylosing spondylitis	3.59e-05	0.000486	CcSEcCtD
Cyclosporine—Skin disorder—Methotrexate—ankylosing spondylitis	3.58e-05	0.000486	CcSEcCtD
Cyclosporine—Hyperhidrosis—Methotrexate—ankylosing spondylitis	3.57e-05	0.000484	CcSEcCtD
Cyclosporine—Vomiting—Triamcinolone—ankylosing spondylitis	3.55e-05	0.000482	CcSEcCtD
Cyclosporine—Vomiting—Methylprednisolone—ankylosing spondylitis	3.54e-05	0.00048	CcSEcCtD
Cyclosporine—Rash—Triamcinolone—ankylosing spondylitis	3.52e-05	0.000478	CcSEcCtD
Cyclosporine—Dermatitis—Triamcinolone—ankylosing spondylitis	3.52e-05	0.000477	CcSEcCtD
Cyclosporine—Anorexia—Methotrexate—ankylosing spondylitis	3.52e-05	0.000477	CcSEcCtD
Cyclosporine—Rash—Methylprednisolone—ankylosing spondylitis	3.51e-05	0.000476	CcSEcCtD
Cyclosporine—Dermatitis—Methylprednisolone—ankylosing spondylitis	3.51e-05	0.000476	CcSEcCtD
Cyclosporine—Urticaria—Prednisone—ankylosing spondylitis	3.51e-05	0.000475	CcSEcCtD
Cyclosporine—Headache—Triamcinolone—ankylosing spondylitis	3.5e-05	0.000474	CcSEcCtD
Cyclosporine—Headache—Methylprednisolone—ankylosing spondylitis	3.49e-05	0.000473	CcSEcCtD
Cyclosporine—Abdominal pain—Prednisone—ankylosing spondylitis	3.49e-05	0.000473	CcSEcCtD
Cyclosporine—Body temperature increased—Prednisone—ankylosing spondylitis	3.49e-05	0.000473	CcSEcCtD
Cyclosporine—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	3.48e-05	0.00361	CbGpPWpGaD
Cyclosporine—Diarrhoea—Betamethasone—ankylosing spondylitis	3.47e-05	0.00047	CcSEcCtD
Cyclosporine—Diarrhoea—Dexamethasone—ankylosing spondylitis	3.47e-05	0.00047	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	3.36e-05	0.000456	CcSEcCtD
Cyclosporine—Dizziness—Dexamethasone—ankylosing spondylitis	3.35e-05	0.000454	CcSEcCtD
Cyclosporine—Dizziness—Betamethasone—ankylosing spondylitis	3.35e-05	0.000454	CcSEcCtD
Cyclosporine—Insomnia—Methotrexate—ankylosing spondylitis	3.34e-05	0.000452	CcSEcCtD
Cyclosporine—Nausea—Triamcinolone—ankylosing spondylitis	3.32e-05	0.00045	CcSEcCtD
Cyclosporine—Paraesthesia—Methotrexate—ankylosing spondylitis	3.31e-05	0.000449	CcSEcCtD
Cyclosporine—Nausea—Methylprednisolone—ankylosing spondylitis	3.31e-05	0.000449	CcSEcCtD
Cyclosporine—Dyspnoea—Methotrexate—ankylosing spondylitis	3.29e-05	0.000446	CcSEcCtD
Cyclosporine—Somnolence—Methotrexate—ankylosing spondylitis	3.28e-05	0.000445	CcSEcCtD
Cyclosporine—Hypersensitivity—Prednisone—ankylosing spondylitis	3.25e-05	0.000441	CcSEcCtD
Cyclosporine—Dyspepsia—Methotrexate—ankylosing spondylitis	3.25e-05	0.00044	CcSEcCtD
Cyclosporine—PPP3CA—Disease—B3GNT2—ankylosing spondylitis	3.24e-05	0.00336	CbGpPWpGaD
Cyclosporine—Vomiting—Dexamethasone—ankylosing spondylitis	3.22e-05	0.000437	CcSEcCtD
Cyclosporine—Vomiting—Betamethasone—ankylosing spondylitis	3.22e-05	0.000437	CcSEcCtD
Cyclosporine—Decreased appetite—Methotrexate—ankylosing spondylitis	3.21e-05	0.000435	CcSEcCtD
Cyclosporine—Rash—Dexamethasone—ankylosing spondylitis	3.2e-05	0.000433	CcSEcCtD
Cyclosporine—Rash—Betamethasone—ankylosing spondylitis	3.2e-05	0.000433	CcSEcCtD
Cyclosporine—Dermatitis—Dexamethasone—ankylosing spondylitis	3.19e-05	0.000433	CcSEcCtD
Cyclosporine—Dermatitis—Betamethasone—ankylosing spondylitis	3.19e-05	0.000433	CcSEcCtD
Cyclosporine—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	3.18e-05	0.000432	CcSEcCtD
Cyclosporine—Fatigue—Methotrexate—ankylosing spondylitis	3.18e-05	0.000431	CcSEcCtD
Cyclosporine—Headache—Dexamethasone—ankylosing spondylitis	3.17e-05	0.000431	CcSEcCtD
Cyclosporine—Headache—Betamethasone—ankylosing spondylitis	3.17e-05	0.000431	CcSEcCtD
Cyclosporine—Asthenia—Prednisone—ankylosing spondylitis	3.17e-05	0.000429	CcSEcCtD
Cyclosporine—Pain—Methotrexate—ankylosing spondylitis	3.15e-05	0.000428	CcSEcCtD
Cyclosporine—Pruritus—Prednisone—ankylosing spondylitis	3.12e-05	0.000423	CcSEcCtD
Cyclosporine—Feeling abnormal—Methotrexate—ankylosing spondylitis	3.04e-05	0.000412	CcSEcCtD
Cyclosporine—Diarrhoea—Prednisone—ankylosing spondylitis	3.02e-05	0.000409	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	3.02e-05	0.000409	CcSEcCtD
Cyclosporine—Nausea—Dexamethasone—ankylosing spondylitis	3.01e-05	0.000408	CcSEcCtD
Cyclosporine—Nausea—Betamethasone—ankylosing spondylitis	3.01e-05	0.000408	CcSEcCtD
Cyclosporine—Urticaria—Methotrexate—ankylosing spondylitis	2.93e-05	0.000397	CcSEcCtD
Cyclosporine—Dizziness—Prednisone—ankylosing spondylitis	2.92e-05	0.000396	CcSEcCtD
Cyclosporine—Body temperature increased—Methotrexate—ankylosing spondylitis	2.92e-05	0.000395	CcSEcCtD
Cyclosporine—Abdominal pain—Methotrexate—ankylosing spondylitis	2.92e-05	0.000395	CcSEcCtD
Cyclosporine—FKBP1A—Spinal Cord Injury—TNF—ankylosing spondylitis	2.9e-05	0.00301	CbGpPWpGaD
Cyclosporine—PPP3CA—MAPK Signaling Pathway—TNF—ankylosing spondylitis	2.82e-05	0.00293	CbGpPWpGaD
Cyclosporine—Vomiting—Prednisone—ankylosing spondylitis	2.81e-05	0.000381	CcSEcCtD
Cyclosporine—Rash—Prednisone—ankylosing spondylitis	2.78e-05	0.000377	CcSEcCtD
Cyclosporine—Dermatitis—Prednisone—ankylosing spondylitis	2.78e-05	0.000377	CcSEcCtD
Cyclosporine—Headache—Prednisone—ankylosing spondylitis	2.76e-05	0.000375	CcSEcCtD
Cyclosporine—Hypersensitivity—Methotrexate—ankylosing spondylitis	2.72e-05	0.000369	CcSEcCtD
Cyclosporine—Asthenia—Methotrexate—ankylosing spondylitis	2.65e-05	0.000359	CcSEcCtD
Cyclosporine—PPP3CA—Signaling by GPCR—PTGER4—ankylosing spondylitis	2.63e-05	0.00273	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—HLA-B—ankylosing spondylitis	2.63e-05	0.00273	CbGpPWpGaD
Cyclosporine—Nausea—Prednisone—ankylosing spondylitis	2.62e-05	0.000355	CcSEcCtD
Cyclosporine—Pruritus—Methotrexate—ankylosing spondylitis	2.61e-05	0.000354	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—HLA-C—ankylosing spondylitis	2.59e-05	0.00269	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	2.56e-05	0.00266	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	2.55e-05	0.00264	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	2.55e-05	0.00264	CbGpPWpGaD
Cyclosporine—Diarrhoea—Methotrexate—ankylosing spondylitis	2.52e-05	0.000342	CcSEcCtD
Cyclosporine—FKBP1A—Disease—B3GNT2—ankylosing spondylitis	2.51e-05	0.0026	CbGpPWpGaD
Cyclosporine—Dizziness—Methotrexate—ankylosing spondylitis	2.44e-05	0.000331	CcSEcCtD
Cyclosporine—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	2.43e-05	0.00252	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	2.42e-05	0.00251	CbGpPWpGaD
Cyclosporine—SLC10A1—Metabolism—B3GNT2—ankylosing spondylitis	2.42e-05	0.00251	CbGpPWpGaD
Cyclosporine—Vomiting—Methotrexate—ankylosing spondylitis	2.35e-05	0.000318	CcSEcCtD
Cyclosporine—Rash—Methotrexate—ankylosing spondylitis	2.33e-05	0.000315	CcSEcCtD
Cyclosporine—PPP3CA—Innate Immune System—CRP—ankylosing spondylitis	2.32e-05	0.00241	CbGpPWpGaD
Cyclosporine—Dermatitis—Methotrexate—ankylosing spondylitis	2.32e-05	0.000315	CcSEcCtD
Cyclosporine—Headache—Methotrexate—ankylosing spondylitis	2.31e-05	0.000313	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—IL1RN—ankylosing spondylitis	2.25e-05	0.00233	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	2.25e-05	0.00233	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—TLR4—ankylosing spondylitis	2.23e-05	0.00231	CbGpPWpGaD
Cyclosporine—Nausea—Methotrexate—ankylosing spondylitis	2.19e-05	0.000297	CcSEcCtD
Cyclosporine—ABCC1—Disease—ANTXR2—ankylosing spondylitis	2.17e-05	0.00225	CbGpPWpGaD
Cyclosporine—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	1.98e-05	0.00205	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—CD79A—ankylosing spondylitis	1.98e-05	0.00205	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling by GPCR—MMP3—ankylosing spondylitis	1.87e-05	0.00194	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—IL1A—ankylosing spondylitis	1.62e-05	0.00168	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—CD40LG—ankylosing spondylitis	1.61e-05	0.00167	CbGpPWpGaD
Cyclosporine—PPIA—Disease—HLA-A—ankylosing spondylitis	1.58e-05	0.00164	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—PTGER4—ankylosing spondylitis	1.56e-05	0.00161	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—HLA-B—ankylosing spondylitis	1.53e-05	0.00159	CbGpPWpGaD
Cyclosporine—ABCB11—Metabolism—B3GNT2—ankylosing spondylitis	1.42e-05	0.00148	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—HLA-A—ankylosing spondylitis	1.42e-05	0.00147	CbGpPWpGaD
Cyclosporine—ABCC3—Metabolism—B3GNT2—ankylosing spondylitis	1.37e-05	0.00142	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—CRP—ankylosing spondylitis	1.35e-05	0.0014	CbGpPWpGaD
Cyclosporine—PPP3CA—Disease—HLA-A—ankylosing spondylitis	1.31e-05	0.00136	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—TLR4—ankylosing spondylitis	1.3e-05	0.00135	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—B3GNT2—ankylosing spondylitis	1.28e-05	0.00133	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—PTGER4—ankylosing spondylitis	1.21e-05	0.00125	CbGpPWpGaD
Cyclosporine—SLCO1A2—Metabolism—B3GNT2—ankylosing spondylitis	1.19e-05	0.00123	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—MMP3—ankylosing spondylitis	1.11e-05	0.00115	CbGpPWpGaD
Cyclosporine—ABCC1—Metabolism—B3GNT2—ankylosing spondylitis	1.07e-05	0.00111	CbGpPWpGaD
Cyclosporine—SLCO1B1—Metabolism—B3GNT2—ankylosing spondylitis	1.02e-05	0.00105	CbGpPWpGaD
Cyclosporine—FKBP1A—Disease—HLA-A—ankylosing spondylitis	1.02e-05	0.00105	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	9.7e-06	0.00101	CbGpPWpGaD
Cyclosporine—ABCG2—Metabolism—B3GNT2—ankylosing spondylitis	9.42e-06	0.000977	CbGpPWpGaD
Cyclosporine—CYP3A7—Metabolism—B3GNT2—ankylosing spondylitis	9.33e-06	0.000968	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—MMP3—ankylosing spondylitis	8.59e-06	0.000891	CbGpPWpGaD
Cyclosporine—CYP3A5—Metabolism—B3GNT2—ankylosing spondylitis	6.75e-06	0.0007	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	5.84e-06	0.000606	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism—B3GNT2—ankylosing spondylitis	5.22e-06	0.000541	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—HLA-A—ankylosing spondylitis	5.17e-06	0.000536	CbGpPWpGaD
Cyclosporine—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	5.09e-06	0.000528	CbGpPWpGaD
Cyclosporine—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	4.8e-06	0.000498	CbGpPWpGaD
Cyclosporine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	4.78e-06	0.000496	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	4.76e-06	0.000493	CbGpPWpGaD
Cyclosporine—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	3.14e-06	0.000325	CbGpPWpGaD
